| Ytd | -55.89% | |
| 1y | -34.28% |
| Open | 4.37 | Prev Close | 4.40 | Low | 4.26 | High | 4.54 | Mkt Cap | 176.58M |
| Vol | 317.34K | Avg Vol | 344.84K | EPS | -3.96 | P/E | N/A | Forward P/E | -5.54 |
| Beta | -0.27 | Short Ratio | 11.43 | Inst. Own | 80.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 6.11 | 200-d Avg | 8.80 | 1yr Est | 26.43 |
TRDA News
Entrada Therapeutics (NASDAQ: TRDA - Get Free Report) and X4 Pharmaceuticals (NASDAQ: XFOR - Get Fre
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced
TRDA stock fell over 15% after Entrada Therapeutics announced initial Phase 1/2 ELEVATE-45-201 study
The DMC recommended initiating Cohort 3 at the top dose of 18 mg/kg, an increase from 12 mg/kg in Co
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELE
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5
Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from $5.61, driven b
Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can
-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support p
BlackRock Inc. purchased a new stake in Entrada Therapeutics, Inc. (NASDAQ: TRDA) during the undefin
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.01 per share versus the Zacks
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.01) per share which beat the ana
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELE
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy a
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committ
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 --
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. See wh
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Entrada Therapeutics (NASDAQ:TRDA)
Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US
Entrada Therapeutics stock plunged after the Duchenne trial data missed investor expectations despit
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.95) per share which beat the ana
Oppenheimer analyst Francois Brisebois maintains Entrada Therapeutics (NASDAQ:TRDA) with a Outper
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.94) per share which beat the ana
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 ---- Co
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Entrada Therapeutics (NASDAQ:TRDA)
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-20
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.06) per share which missed the a
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.04) per share which missed the a
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.42) per share which beat the ana
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)
ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly earnings of $0.03 per share which beat the ana
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)